Company research
Pharvaris N.V.
CIK 1830487Updated Nov 17, 2026
PHVS price & chart
Loading TradingView…
NASDAQ:PHVS on TradingView ↗About the company
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.
In the news
No coverage from other publishers is available.
Seeking Alpha
Pharvaris N.V. (PHVS) Presents at 2026 HAEi Regional Conference Americas - Slideshow ↗
Pharvaris rises after BofA upgrades to Buy ↗
SEC disclosures
Pharvaris N.V. files prospectus supplement (424B5) ↗
Financials
FY 2025 · EURSource
Source
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||
| Profit or LossEUR | -45,480,686Source | -29,731,073Source | -21,897,873Source | -12,621,068Source | -15,202,773Source | -175,699,397Source | -134,221,527Source | -100,875,068Source | -76,332,557Source |
| Additional Financial Items | |||||||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | 48,591Source | -290Source | 0Source | — | — | -1,052,878Source | 98,564Source | -2,819,253Source | — |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR | — | — | — | — | — | -331,339Source | -34,316Source | -41,051Source | 317,612Source |
| AdjustmentsForFinanceCostsEUR | — | — | — | — | — | — | — | — | 39,254Source |
| AdjustmentsForIncomeTaxExpenseEUR | — | — | — | — | — | -2,168,735Source | -2,767,247Source | -1,108,410Source | -182,824Source |
| AdjustmentsForSharebasedPaymentsEUR | — | — | — | — | — | 19,050,394Source | 16,208,533Source | 10,663,226Source | 11,349,200Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsEUR | — | — | — | — | — | 11,742,407Source | -7,329,038Source | 2,794,435Source | -11,100,392Source |
| GeneralAndAdministrativeExpenseEUR | 10,765,189Source | 11,314,067Source | 7,773,430Source | 7,660,133Source | 4,664,726Source | 45,344,598Source | 47,124,638Source | 31,338,590Source | 29,339,034Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | 219,013Source | 159,657Source | 220,507Source | 119,527Source |
| ProceedsFromIssuingSharesEUR | — | — | — | — | — | — | — | — | 9,609,865Source |
income statement · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Additional Financial Items | |||||||||
| ApplicableTaxRatenumber | 0.26Source | 0.26Source | 0.26Source | 0.26Source | — | 0.26Source | 0.26Source | 0.26Source | 0.26Source |
| AverageEffectiveTaxRatenumber | — | — | — | — | — | -0.01Source | -0.01Source | -0.01Source | -0.01Source |
| BasicEarningsLossPerShareEUR/shares | -0.83Source | -0.55Source | -0.63Source | -0.38Source | -0.46Source | -2.97Source | -2.48Source | -2.63Source | — |
| CurrentTaxExpenseIncomeEUR | 157,772Source | 70,623Source | 94,178Source | 2,741,102Source | 2,965Source | 1,087,278Source | 1,033,115Source | 473,623Source | 757,413Source |
| DepreciationRightofuseAssetsEUR | — | — | — | — | — | 229,203Source | 174,799Source | 197,770Source | 114,020Source |
| DilutedEarningsLossPerShareEUR/shares | -0.83Source | -0.55Source | -0.63Source | -0.38Source | -0.46Source | -2.97Source | -2.48Source | -2.63Source | — |
| EmployeeBenefitsExpenseEUR | 15,127,267Source | 10,858,498Source | 7,978,587Source | 6,886,187Source | 3,555,390Source | 58,894,977Source | 46,650,892Source | 32,446,666Source | 26,819,346Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | — | — | — | — | — | 11,200,000Source | 10,500,000Source | 6,200,000Source | 7,590,041Source |
| GeneralAndAdministrativeExpenseEUR | 10,765,189Source | 11,314,067Source | 7,773,430Source | 7,660,133Source | 4,664,726Source | 45,344,598Source | 47,124,638Source | 31,338,590Source | 29,339,034Source |
| IncomeTaxExpenseContinuingOperationsEUR | 202,782Source | 70,623Source | 94,178Source | 2,741,102Source | 2,965Source | 1,987,901Source | 1,825,024Source | 1,048,805Source | 679,087Source |
| InterestExpenseEUR | — | — | — | — | — | — | — | — | 16,105Source |
| InterestExpenseOnLeaseLiabilitiesEUR | — | — | — | — | — | 428,846Source | 500,161Source | 15,803Source | 41,633Source |
| OtherEmployeeExpenseEUR | 72,108Source | 0Source | — | — | — | 630,805Source | — | — | — |
| OtherFinanceCostEUR | 38,131Source | 9,803Source | 4,879Source | 550Source | 3,021Source | 172,861Source | 46,914Source | 20,475Source | 23,149Source |
| ProfessionalFeesExpenseEUR | 1,686,774Source | 2,155,727Source | 1,294,705Source | 911,170Source | 324,793Source | 8,616,327Source | 7,757,750Source | 4,689,462Source | 3,972,771Source |
| ProfitLossBeforeTaxEUR | — | — | — | — | — | -173,711,496Source | -132,396,503Source | -99,826,263Source | -75,653,470Source |
| ProfitLossFromOperatingActivitiesEUR | -45,277,904Source | -29,660,450Source | -21,803,695Source | -9,879,966Source | -15,199,808Source | -173,711,496Source | -132,396,503Source | -99,826,263Source | -75,653,470Source |
| ResearchAndDevelopmentExpenseEUR | 29,607,908Source | 23,067,934Source | 14,681,935Source | 13,721,637Source | 8,060,599Source | 124,478,334Source | 98,563,529Source | 65,575,030Source | 57,375,574Source |
| ProfitLossAttributableToOwnersOfParent | — | — | —Source | —Source | —Source | — | — | — | — |
Filing attachments
phvs-ex99_1.htm · 6-K · 2026-11-12
Exhibit 99.1 Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update • Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027 • Topline data from part 1 of CREAATE, a pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks, expected in 1Q2027; enrollment ongoing in part 2 of CREAATE evaluating deucrictibant IR for the on-demand treatment of AAE-C1INH attacks • Preparation of NDA dossier of deucrictibant XR…
Read attachment ↗phvs-ex99_2.htm · 6-K · 2026-11-12
Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes thereto, for the three and nine months ended September 30, 2026 and 2025 included as Exhibit 99.3 to th…
Read attachment ↗phvs-ex99_1.htm · 6-K · 2026-09-08
September 8, 2026 CHAPTER-3 Topline Data This presentation includes data for an investigational product not yet approved by regulatory authorities. Exhibit 99.1 Disclaimer This Presentation contains certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, without …
Read attachment ↗phvs-ex99_1.htm · 6-K · 2026-09-08
Exhibit 99.1 Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks • Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE • 87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2 • All secondary efficacy endpoints met with statistical significance • Well-tolerated safety profile of deucrictibant XR d…
Read attachment ↗phvs-ex99_1.htm · 6-K · 2026-08-12
Exhibit 99.1 Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update • Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 • Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026 • Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks • Strong financ…
Read attachment ↗phvs-ex99_2.htm · 6-K · 2026-08-12
Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes thereto, for the three and six months ended June 30, 2026 and 2025 included as Exhibit 99.3 to the Repo…
Read attachment ↗